Copanlisib for Treatment of B-Cell Malignancies: The Development of a PI3K Inhibitor With Considerable Differences to Idelalisib

Drug Design, Development and Therapy - New Zealand
doi 10.2147/dddt.s142406
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited